# A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol

> **NCT03467113** · PHASE1 · COMPLETED · sponsor: **Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.** · enrollment: 9 (actual)

## Conditions studied

- Dravet Syndrome
- Lennox Gastaut Syndrome

## Interventions

- **DRUG:** ZX008 0.2 to 0.8 mg/kg/day
- **DRUG:** Cannabidiol

## Key facts

- **NCT ID:** NCT03467113
- **Lead sponsor:** Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-19
- **Primary completion:** 2020-06-24
- **Final completion:** 2020-06-24
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2023-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03467113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03467113, "A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03467113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*